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ABSTRACT:
Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its 
downstream effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly 
activated in acute myeloid leukemia (AML) patients, where it contributes to leukemic 
cell proliferation, survival, and drug-resistance. Thus, inhibiting mTOR signaling in 
AML blasts could enhance their sensitivity to cytotoxic agents. Preclinical data also 
suggest that allosteric mTOR inhibition with rapamycin impaired leukemia initiating 
cells (LICs) function. In this study, we assessed the therapeutic potential of a 
combination consisting of temsirolimus [an allosteric mTOR complex 1 (mTORC1) 
inhibitor] with clofarabine, a nucleoside analogue with potent inhibitory effects on 
both ribonucleotide reductase and DNA polymerase. The drug combination (CLO-
TOR) displayed synergistic cytotoxic effects against a panel of AML cell lines and 
primary cells from AML patients. Treatment with CLO-TOR induced a G0/G1-phase cell 
cycle arrest, apoptosis, and autophagy. CLO-TOR was pro-apoptotic in an AML patient 
blast subset (CD34+/CD38-/CD123+), which is enriched in putative leukemia initiating 
cells (LICs). In summary, the CLO-TOR combination could represent a novel valuable 
treatment for AML patients, also in light of its efficacy against LICs.
INTRODUCTION
Acute myeloid leukemia (AML) is defined as 
a clonal disorder characterized by the uncontrolled 
proliferation and survival of immature myeloid progenitors 
that undergo a differentiation block at various maturation 
steps, leading to accumulation of leukemic cells in bone 
marrow and inhibition of normal hematopoiesis [1]. 
Despite advances in the treatment, the cure of patients 
with AML remains challenging and difficult [2]. In 
fact, although intensive chemotherapy induces disease 
remission in a large number of patients, many of them 
eventually relapse and die. In particular, the outcome of 
patients aged ≥60 years remains highly disappointing 
[3]. Elderly patients respond less satisfactory to standard 
chemotherapy than younger individuals, as reflected by 
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higher incidence of treatment-related mortality, lower 
complete remission rates, and shorter survival in major 
clinical trials [4, 5]. Overall, AML prognosis remains 
dismal and new therapeutic approaches are therefore under 
active investigation [6]. In AML, aberrant activation of 
several signal transduction pathways enhances survival, 
proliferation, and drug-resistance of leukemic cells. 
Therefore, these signaling cascades are attractive targets 
for the development of innovative therapeutic strategies 
for AML patients [7]. One promising target for molecular 
therapy in AML is the phosphatidylinositol 3-kinase 
(PI3K)/Akt/mechanistic target of rapamycin (mTOR) 
signaling pathway, which is constitutively activated in 70-
90% of AML patients and has been shown to be central to 
the proliferation, survival, and drug-resistance of leukemic 
cells [8, 9]. A major problem in the efforts to treat AML 
is the inability of current therapies to efficiently target and 
eliminate leukemia initiating cells (LICs), which are the 
cells that are thought to initiate and maintain the leukemic 
phenotype [10]. The majority of LICs are quiescent and 
therefore not sensitive to various chemotherapeutic agents 
that kill rapidly dividing cells [11]. This fact could explain 
the difficulties in eradicating AML with chemotherapy 
alone and the relapses seen in the majority of patients, 
despite initial complete responses with drugs regimens 
[12]. However, mTOR inhibitors, such as rapamycin, have 
displayed cytotoxic activity against LICs in pre-clinical 
models of AML [13].
In a recent multicenter, open-label phase II trial 
(AML1107) performed by the GIMEMA cooperative 
group, it has been studied the efficacy and safety of the 
drug combination consisting of low-dosage clofarabine 
with the allosteric mTOR complex 1 (mTORC1) inhibitor 
temsirolimus (CCI-779, Torisel©) in a group of elderly 
patients with refractory/relapsed AML [14]. The results 
from this study documented that temsirolimus could be 
safely combined with low-dosage clofarabine and that 
the combination displayed some encouraging clinical 
activity [14]. Clofarabine is a a second-generation 
purine nucleoside analogue which has been synthesized 
to overcome the limitations and incorporate the best 
properties of fludarabine and cladribine. Clofarabine 
mainly acts by inhibiting ribonucleotide reductase and 
DNA polymerase, thereby depleting the amount of 
intracellular deoxynucleoside triphosphates available for 
DNA replication [15]. However, clofarabine displayed 
cytotoxic activity also against non-proliferating leukemia 
cells, by directly targeting the mitochondria and inducing 
apoptosis [16]. 
In the present study, we have investigated the in 
vitro effects of the clofarabine-temsirolimus (henceforth 
CLO-TOR) combination on a panel of AML cell lines 
and primary cells from AML patients. Our results 
could contribute to design in the future more effective 
therapeutic protocols based on these two drugs.  
RESULTS
The CLO-TOR combination has synergistic 
cytotoxic effects in AML cells
The effects of clofarabine, temsirolimus, and 
their combination (CLO-TOR) on AML cell lines 
were analyzed by first treating the cells with increasing 
concentrations of the drugs and then measuring the rates 
of survival by MTT assays. Cell lines (U937, HL-60, 
OCI-AML3, THP-1, and MOLM-13) were cultured in 
the presence of clofarabine or temsirolimus either alone 
or in combination at a fixed ratio (1:1) for 24 h (Fig. 1A). 
The combined treatment was highly effective in inducing 
cytotoxicity in all of the cell lines. The combination 
index (CI) values, calculated with Calcusyn software for 
dose-effect analysis, indicated the existence of a strong 
synergism between clofarabine and temsirolimus (CI<0.3), 
especially at lower and intermediate drug concentrations. 
The effects of the drugs on proliferation of THP-1 and 
MOLM-13 cell lines were analyzed also by cell counting. 
Exponentially growing cells were seeded and incubated 
with clofarabine (100 nM), temsirolimus (100 nM), and 
CLO-TOR (both drugs at 100 nM) for 24 h, then viable 
cells were counted. Analysis of the results demonstrated 
that CLO-TOR was more efficacious than either treatment 
alone in blocking cell proliferation (Fig.1B). To better 
assess the effectiveness of CLO-TOR as a potential 
therapeutic combination in AML, we examined the 
activation of the PI3K/Akt/mTOR pathway in 12 AML 
patient samples isolated from bone marrow or peripheral 
blood. Pathway activation was studied by flow cytometry, 
after staining the samples with a phycoerythrin (PE)-
conjugated anti-CD33 and a PC7-conjugated anti-CD45 
antibody, followed by intracellular staining for either Ser 
473 p-Akt or Ser 235/236 p-S6 ribosomal protein (S6RP). 
Therefore, blast cells could be positively identified by 
CD33/CD45/side scatter gating (Fig.1C). All of the 
analyzed samples displayed activation of the signaling 
pathway, as documented by phosphorylation of both Akt 
and S6RP (Fig.1 C). 
AML primary cells were then treated with the drugs, 
and cell viability was analyzed by MTT assays. A marked 
reduction in cell viability at 96 h was detected (Fig.1D). 
In Fig.1D it is shown a patient who was very sensible to 
CLO-TOR and a patient more resistant to the treatment, 
but in whom nevertheless the CLO-TOR combination 
displayed a strong synergism, with CIs < 0.4. Of the 12 
analyzed patients, 8 were sensitive whereas 4 displayed 
various degree of resistance to the drug combination. 
Overall, these findings demonstrated that the CLO-TOR 
combination has a synergistic cytotoxic activity also 
against primary cells from AML patients with up-regulated 
PI3K/Akt/mTOR signaling. 
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The CLO-TOR combination has pro-apoptotic 
effects on AML cell lines and block cells in the G0/
G1 phase of the cell cycle 
It was then investigated whether cell viability 
impairment could be related to apoptosis, using Annexin 
V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) 
staining in AML cell lines. After 8 h of treatment, flow 
cytometric analysis documented that CLO-TOR was more 
effective than either treatment alone in inducing apoptosis 
(Fig. 2A). Western blotting analysis of protein extracts 
from AML cell lines treated with CLO-TOR documented 
the cleavage of procaspase-8, -9 and -3 (Fig. 2B). 
Given the fundamental role played by PI3K/Akt/
mTOR signaling in the control of cell proliferation, the 
effects of CLO-TOR on cell cycle progression were also 
investigated. Flow cytometric analysis of PI-stained 
U937 AML cells treated for 24 h with clofarabine or 
temsirolimus either alone or in combination documented 
a marked increase in G
0
/G
1
 phase cells with a decrease in S 
and G
2
/M phase cells. Again, the combined treatment was 
more effective than either treatment alone (Fig. 2C). Cell 
cycle arrest in G
0
/G
1
 was accompanied by an increase in 
the expression of p27Kip1, a negative regulator of cell cycle 
progression whose levels are under the control of mTOR 
signaling [17]. However, the CLO-TOR combination was 
more effective than temsirolimus alone in inducing p27Kip1 
expression and this was consistent with the effects on cell 
cycle progression.  
The CLO-TOR combination induces autophagy
As mTORC1 is an inhibitor of autophagy, it was 
investigated whether the CLO-TOR combination could 
Figure 1: CLO-TOR affects viability of AML cell lines and blasts from AML patients with constitutively active PI3K/
Akt/mTOR signaling pathway. A: MTT assays performed after 24 h of treatment with the drugs. Results are the mean of at least three 
different experiments ± s.d. The combination index (CI) value for each data point was calculated with the appropriate software for dose 
effect analysis (CalcuSyn). B: To assess cell proliferation, 3 x 105 cells were seeded in 25 cm2 flasks and growth curves were determined 
by direct count of cells harvested at 24 h after seeding. Viable cells were counted in a hemocytometer, using 0.2% Trypan Blue. C: Primary 
cells from AML patients, gated for CD33+/CD45low expression (red rectangle), were fixed, permeabilized, stained with AlexaFluor®488-
conjugated antibodies to either Ser 473 p-Akt, or Ser 235/236 p-S6RP, then analyzed by flow cytometry. Two representative patients are 
shown. Panel D: MTT assays of AML primary cells treated with clofarabine, temsirolimus, or CLO-TOR for 96 h. Results are the mean of 
at least three different experiments ± SD. The combination index (CI) value for each data point was calculated as detailed above. In A,B, 
and D, CTRL, untreated cells; CLO, clofarabine ; TOR, temsirolimus. 
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induce autophagy in AML cells. Induction of autophagy 
was confirmed by transmission electron microscopy 
(TEM) analysis, which documented the presence of 
autophagic vacuoles in the cytoplasm of MOLM-13 
cells (Fig. 3A). However, TEM analysis after CLO-TOR 
treatment also revealed the presence of apoptotic cells 
and, intriguingly, we found both apoptotic and autophagic 
features in the same cells (Fig.3A). To confirm induction 
of autophagy, we studied the expression levels of both 
beclin-1 and LC3B I/II, two recognized autophagy markers 
[18]. Western blot analysis demonstrated an increase in 
the expression of both beclin-1 and of the fast migrating 
form of LC3B (LC3B II, 14 kDa), while LCB I (16 kDa) 
decreased (Fig. 3B). It is worth remembering here that 
LC3B-II is bound to the membrane of autophagosome 
[19]. 
The CLO-TOR combination affects PI3K/Akt/
mTOR signaling and p-ERK levels in AML cell 
lines
We studied the effects of increasing concentrations 
of the drugs administered alone or in combination for 
24 h on components of the PI3K/Akt/mTOR signaling 
pathway. Western blotting analysis documented that 
dephosphorylation of various key components of the 
signaling network (Akt, S6RP, 4E-BP1) was mainly 
due to the effect of either temsirolimus or CLO-TOR 
combination, while clofarabine alone was not able to 
induce a significant modulation of this signaling cascade 
(Fig.4A). Overall, CLO-TOR was more powerful than 
temsirolimus alone in inducing protein dephosphorylation. 
Figure 2: CLO-TOR induces apoptosis and cell cycle arrest in the G0/G1 phase of cell cycle. A: Flow cytometric analysis 
of Annexin V-FITC/PI stained AML cell lines treated for 8 h with 100 nM clofarabine (CLO), 100 nM temsirolimus (TOR), or  the CLO-
TOR combination (100 nM + 100 nM). The percentages of early apoptotic cells (Annexin-V FITC+/PI-, lower right quadrant) and late 
apoptotic/necrotic cells (Annexin-V FITC+/PI+, upper right quadrant) are indicated. The histograms are representative of three separate 
experiments. CTRL: untreated cells. B: Western blot analysis documenting the activation of caspase-8, caspase-9, and -3 by CLO-TOR 
(100 nM + 100 nM). Cells were treated with CLO-TOR for the indicated times, collected, and then lysed. Fifty micrograms of each lysate 
were electrophoresed on SDS-PAGE gels, followed by transfer to nitrocellulose membranes. An antibody to GAPDH demonstrated equal 
lane loading. Molecular weights are indicated at right. C: Flow cytometric analysis of PI-stained U937 cells after 24 h of treatment with 
clofarabine (CLO, 100 nM), temsirolimus (TOR, 100 nM), or the CLO-TOR combination (100 nM + 100 nM). One representative of three 
separate experiments is shown.  D: Western blot analysis documenting concentration-dependent, increased expression of p27Kip1 in U937 
cells treated with the drugs for 24 h. An antibody to β-actin demonstrated equal lane loading. Molecular weights are indicated at right. 
CTRL, untreated cells; CLO, clofarabine; TOR, temsirolimus. 
Oncotarget 2012; 3: 1615-16281619www.impactjournals.com/oncotarget
The decrease in the levels of Ser 473 p-Akt was consistent 
with the capacity of CLO-TOR combination to inhibit 
also mTORC2, which is involved in Ser 473 p-Akt 
phosphorylation [20]. 
Considering the relevance of ERK signaling in AML 
cells [21, 22], it was analyzed the phosphorylation levels 
of ERK 1/2 in MOLM-13 cells treated with the drugs. 
Western blotting analysis documented that clofarabine 
slightly decreased p-ERK 1/2 levels, whereas temsirolimus 
dramatically increased them. However, the CLO-TOR 
combination completely prevented the increase in p-ERK 
1/2 induced by temsirolimus (Fig. 4B). 
The CLO-TOR combination modulates STAT3 
and c-Myc in AML cells
It is well known that up-regulated STAT3 activity 
is associated with several human tumors, including 
AML [23] and that STAT3 inhibition can mediate tumor 
regression [24]. Recently, it has been documented that 
mTORC2 controls phosphorylation of STAT3 at Ser 727 
[25]. Therefore, we analyzed Ser 727 p-STAT3 levels 
in MOLM-13 cells treated with the drugs. Western blot 
analysis demonstrated that STAT3 was dephosphorylated 
at Ser 727 maximally after treatment with CLO-TOR for 
48 h (Fig. 5A). However, we also observed a reduction in 
Figure 3: CLO-TOR induces autophagy in MOLM-13 cells. A: Cells were treated for the indicated times with CLO-TOR (100 
nM + 100 nM), then processed for TEM analysis that documented both autophagy and apoptosis induction. Large cytoplasmic vacuoles 
containing various degraded organelles are evident, as well as condensed apoptotic chromatin (arrow). The original magnification of the 
micrographs is indicated. B: Western blot analysis for Beclin-1 and LC3B I/II expression in MOLM-13 cells treated with CLO-TOR (100 
nM + 100 nM) for the indicated times. An antibody to β-actin demonstrated equal lane loading. Molecular weights are indicated at right. 
In A and B, CTRL, untreated cells.
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the amount of total STAT3. Quantitative real-time PCR 
(qRT-PCR) analysis documented that this reduction was 
likely due to decreased expression of the STAT3 gene, that 
was detected in all AML cell lines already after 24 h of 
treatment with CLO-TOR (Fig. 5B). Similar results were 
detected in AML primary cells (data not shown).
Phosphorylation of STAT3 at Ser 727 is necessary, 
in addition to tyrosine phosphorylation, for full activation 
of STAT3-dependent transcription [26]. Known STAT3 up-
regulated genes include Bcl-xL, Mcl-1, survivin, Akt, and 
c-Myc [27]. Therefore, we analyzed the levels of c-Myc 
by both qRT-PCR and western blotting that documented a 
marked decrease in the expression of c-Myc mRNA and 
protein in all AML cell lines we studied (Fig. 5C-D). 
Effects of CLO-TOR on mTORC1 signaling and 
p-ERK 1/2 in AML primary cells
We analyzed the effect of CLO-TOR on mTORC1 
signaling and p-ERK 1/2  in 12 AML patient samples. 
Three representative patients are presented in Fig. 6A. 
Overall, the CLO-TOR combination was more powerful 
than either drug alone in dephosphorylating both p70S6 
kinase (p70S6K) and 4E-BP1. However, in contrast to the 
results obtained using MOLM-13 cells, the drugs did not 
result in either increased or decreased phosphorylation of 
ERK 1/2 in AML primary cells. 
Figure 4: CLO-TOR affects the phosphorylation state of critical components of the PI3K/Akt/mTOR signaling 
pathway, as well as p-ERK 1/2 levels in AML cell lines. A: Cells were treated with clofarabine (CLO), temsirolimus (TOR), or the 
drug combination (CLO-TOR) at the indicated concentrations for 24 h, collected, and lysed. Western blot analysis was then performed. B: 
Western blot analysis documenting changes in p-ERK 1/2 levels in MOLM-13 cells treated with the single drugs (100 nM) or CLO-TOR 
(100 nM + 100 nM) for the indicated times. In A and B, 50 µg of each lysate were electrophoresed on SDS-PAGE gels, then blotted to 
nitrocellulose membranes. An antibody to β-actin demonstrated equal lane loading. Molecular weights are indicated at right. In A and B, 
CTRL, untreated cells. 
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Figure 5: CLO-TOR modulates STAT3 and c-Myc expression in AML cell lines. A: Western bot analysis for STAT-3 and Ser 
727 p-STAT3 in MOLM-13 cells treated with clofarabine (CLO, 100 nM), temsirolimus (TOR, 100 nM), or CLO-TOR (100 nM + 100 
nM) for 48 h. B: Western blot analysis documenting a time-dependent reduction in STAT3 expression levels in MOLM-13 cells treated 
with CLO-TOR (100 nM + 100 nM). In A and B, an antibody to β-actin demonstrated equal lane loading. Molecular weights are indicated 
at right. B: qRT-PCR for STAT3 mRNA expression in AML cell lines treated with CLO-TOR (100 nM + 100 nM) for 24 h. Results are the 
mean from three different experiments ± s.d. C: qRT-PCR for c-Myc mRNA expression in AML cell lines treated with CLO-TOR (100 nM 
+ 100 nM) for 24 h. Results are the mean from 3 different experiments ± s.d. In A-C, CTRL, untreated cells. D: Western bot analysis for 
c-Myc protein expression in AML cell lines treated with different concentration of CLO-TOR for 48 h. An antibody to β-actin documented 
equal lane loading. Molecular weights are indicated at right.
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eIF4F complex formation is down-regulated by 
CLO-TOR treatment in AML patient samples
Translation of mRNA is tightly regulated at the 
initiation level through the assembly of eIF4F complexes. 
The phosphorylation of 4E-BP1 is the limiting step in 
the assembly of the translation initiating complex eIF4F, 
initiated by the interactions between the eIF4E and eIF4G 
proteins [28, 29]. It has been documented that rapamycin 
and rapalogs were not effective at blocking the formation 
of the eIF4F complex in acute leukemia cells, owing to 
incomplete dephosphorylation of 4E-BP1 [30, 31]. We 
thus performed 7-methyl-GTP pull-down assays in patient 
samples treated with CLO-TOR to study the interactions 
between eIF4E and eIF4G (active translation) or 4E-BP1 
(inactive translation). CLO-TOR decreased the amount 
of eIF4G associated with eIF4E, whereas the amount of 
4E-BP1 associated with eIF4E increased, thus switching 
translation to an inactive state (Fig. 6B). Western blots 
analysis performed on whole-cell lysates documented that 
the drug combination did not significantly reduce eIF4G, 
eIF4E, or 4E-BP1 expression. 
Figure 6: CLO-TOR affects mTORC1 signaling and eIF4F complex formation in AML patient samples. A: AML patient 
samples were cultured for 24 h in the presence of clofarabine (CLO, 100 nM), temsirolimus (TOR, 100 nM), or CLO-TOR (100 nM + 100 
nM). Cell lysates were clarified by centrifugation, separated by SDS-PAGE and blotted to nitrocellulose membranes that were incubated 
with antibodies to Thr 389 p-p70S6K, p70S6K, Thr 37/46 p-4E-BP1, 4E-BP1, Thr 202/Tyr 204 p-ERK 1/2, and ERK 1/2. An antibody 
to β-actin documented equal lane loading. Molecular weights are indicated at right. Three representative samples are shown. CTRL, 
untreated cells. B: AML patient primary cells treated with CLO-TOR (100 nM) were lysed in solubilizing buffer. Lysates were clarified by 
centrifugation and incubated with 7-methyl-GTP-Sepharose beads in binding buffer. Beads were then washed three times in binding buffer 
and boiled in Laemmli’s sample buffer. Protein levels were then analyzed by western blot. Two representative patients are shown. CTRL, 
untreated cells. 
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Figure 7: CLO-TOR induces apoptosis and modulates PI3K/Akt/mTOR signaling in the CD34+/CD38-/CD123+ AML 
patient subpopulation. A: Primary cells from AML patients were gated for CD34/CD38/CD123 expression, then the CD34+/CD38-/
CD123+ cell subset was analyzed for positivity to Annexin V by flow cytometry, after 24 h of treatment with clofarabine (100 nM, CLO), 
temsirolimus (100 nM, TOR), or CLO-TOR combination (100 nM + 100 nM). One representative patient is shown. CTRL, untreated cells. 
B: Primary AML cells were incubated with CLO-TOR (100 nM + 100 nM) for 24 h. After electronic gating on the CD34+/CD38- cell subset, 
CD123+ positive cells were analyzed for Ser 473 p-Akt expression levels by flow cytometry. C: As in B, with the exception that putative 
AML LICs cells were analyzed for Ser 235/236 p-S6RP. In B and C one representative patient is shown. CTRL, untreated cells. 
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The CLO-TOR combination targets the CD34+/
CD38-/CD123+ AML cell subset 
Relapses from AML are thought to originate from 
the outgrowth of a leukemic subpopulation (CD34+/CD38-/
CD123+) displaying both self-renewal and drug-resistance, 
referred to as LICs. Therefore, it was investigated whether 
CLO-TOR could induce apoptosis this AML patient cell 
subset. After electronic gating on the CD34+/CD38-/
CD123+ subpopulation, cells were analyzed for positivity 
to Annexin V staining. After 24 h of treatment, the CLO-
TOR combination was significantly more effective in 
inducing apoptosis than the single drugs (Fig. 7A). The 
CLO-TOR combination was also able to induce a marked 
dephosphorylation of both Ser 473 p-Akt (Fig. 7B) and Ser 
235/236 p-S6RP (Fig. 7C) in the CD34+/CD38-/CD123+ 
cell subset, implying a down-modulation of mTORC1/2 
signaling activity in LICs.
DISCUSSION
Chemotherapy is at present the treatment of choice 
for treating AML patients [32]. However, great interest 
surrounds the development of novel, lees toxic, targeted 
therapies, especially for elderly patients [33, 34]. Here, 
we have evaluated the in vitro effects of the CLO-TOR 
combination on AML cell lines and patient samples. 
CLO-TOR reduced cell viability in a panel of AML cell 
lines and primary cells from AML patients. The combined 
treatment increased the percentage of cells in the G
0
/G
1
 
phase of the cell cycle. Inhibition of cell proliferation 
correlated with up-regulation of the CDK inhibitor p27Kip1. 
It is known that mTOR controls the expression of the 
p27Kip1 gene through the Oct 1 transcription factor [35]. 
Nevertheless, we do not know why clofarabine, when 
administered with temsirolimus, potentiated the induction 
of p27Kip1 expression.
Moreover, the CLO-TOR combination induced 
apoptosis, as documented by cleavage of caspase-3, -8, 
and .9. These findings indicated that both the intrinsic 
and extrinsic pathway of apoptosis were activated upon 
incubation with the drugs. However, we observed that 
also autophagy was activated in response to CLO-
TOR. It should be reminded here that mTORC1 inhibits 
autophagy [36]. Interestingly, while clofarabine alone 
predominantly induced apoptosis (data not shown), 
the CLO-TOR treatment induced both apoptosis and 
autophagy in the same cell. Since autophagy could be 
a protective mechanism against the cytotoxic effects of 
chemotherapeutic drugs [37], it will be interesting in the 
future to assess if inhibition of autophagy could increase 
the cytotoxicity of the CLO-TOR combination. 
CLO-TOR was capable of inhibiting the 
phosphorylation of Akt on Ser 473 as well as 
phosphorylation of the mTORC1 downstream targets, 
p70S6K,  S6RP, and 4E-BP1 in the cell lines and patient 
samples analyzed. Down-regulation of Ser 473 p-Akt 
levels demonstrated that the drug combination was able 
to inhibit also mTORC2 activity. This observation is 
noteworthy, as previous studies have highlighted that 
a major limitation of rapamycin and its analogs is that 
they could actually up-regulate p-Akt levels in AML 
cells [38]. The ability of CLO-TOR to down-modulate 
phosphorylation of 4E-BP1 is also important, as Tamburini 
et al. [30] emphasized that the weak anti-leukemic activity 
of the rapalogs was mainly due to the sustained high level 
of 4E-BP1 phosphorylation in AML cells treated with these 
compounds. Conversely, we showed herein that the CLO-
TOR combination blocked 4E-BP1 phosphorylation at Thr 
37/46  in AML patient samples. Indeed, phosphorylation 
of 4E-BP1 is the limiting step for the assembly of the 
translation-initiating complexes. As a consequence of 4E-
BP1 dephosphorylation, CLO-TOR inhibited the assembly 
of eIF4F-initiating complexes, as we have demonstrated. 
This could result in a global inhibition of protein synthesis 
and thus a decreased expression of oncogenic proteins 
regulated at the translation initiation level [39]. 
Another limitation of rapalogs is that mTORC1 
inhibition led to the activation of ERK 1/2 in a variety 
of cancer cell lines and primary tumor cells, as well as 
in a cohort of patients with metastatic disease who had 
undergone therapy with RAD-001 [40]. Mechanistically, 
it has been demonstrated that ERK 1/2 activation could 
be mediated by a p70S6K-PI3K-Ras signaling pathway 
[40]. However, the impact of rapalogs on ERK 1/2 
phosphorylation levels has never been studied in AML 
cells. Temsirolimus dramatically increased ERK 1/2 
phosphorylation in MOLM-13 cells and, intriguingly, 
this increase was completely blocked by co-treatment 
with clofarabine. Nevertheless, we have not detected any 
changes in p-ERK 1/2 levels in AML primary cells treated 
with temsirolimus. Therefore, the effects of rapalogs 
on ERK 1/2 signaling in AML cells is an issue that will 
require further investigation, using a panel of AML cell 
lines and a larger number of patient samples. 
Another interesting observation emerging from our 
study is that CLO-TOR treatment affected the transcription 
of the STAT3 gene in AML cell lines and patient samples. 
It has been documented that STAT3 gene expression is 
regulated by mTOR signaling in cancer cells [41, 42], 
however, it is not clear why the addition of clofarabine 
to temsirolimus resulted in further down-regulation of 
STAT3 gene.  
Consistently with the down-regulation of STAT3 
expression and phosphorylation, CLO-TOR caused a 
decreased expression of c-Myc gene and protein levels. 
c-Myc expression down-regulation may be very important 
for explaining the cytotoxic effects of CLO-TOR, as a 
decrease in c-Myc levels could result in the inhibition of 
ribosome synthesis that in turn causes proliferative arrest 
or have irreversible consequences, including apoptosis 
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We have also documented that CLO-TOR treatment 
caused apoptosis in the CD34+/CD38-/CD123+ cell subset 
that is enriched in LICs. Importantly, the combined 
treatment was more effective than either drug alone 
in inducing apoptotic cell death in this subpopulation. 
Moreover, CLO-TOR was able to down-regulate the 
phosphorylation of Akt at Ser 473 and of S6RP at Ser 
235/236, implying targeting of both mTORC1 and 
mTORC2 in the CD34+/CD38-/CD 123+ subset.
Although clofarabine is used for the treatment 
of acute leukemias both in the adults and children [44, 
45], surprisingly there are very few data in the literature 
regarding the effects of this drug on signaling pathways 
that are up-regulated in leukemic cells. It has been 
documented that clofarabine induced dephosphorylation 
of Akt and some of its down-stream targets (Bad 
and FOXO3A) in CCRF-CEM acute lymphoblastic 
leukemia cells [46]. Moreover, clofarabine decreased the 
expression of anti-apoptotic molecules, including Mcl-1 
and Bcl-XL. Here, we have demonstrated that clofarabine 
potentiated the effects of temsirolimus on p27Kip1 and 
STAT3 expression, as well as on the phoshorylation 
levels of Akt, p70S6K, S6RP, and 4E-BP1. It is at present 
unclear how clofarabine could influence gene expression 
and protein phosphorylation. However, further studies 
of these additional effects of clofarabine will be of the 
utmost importance, as they could help in designing more 
efficacious therapeutic protocols, combining clofarabine 
and signal trasduction modulators, for the treatment of 
acute leukemia patients.     
MATERIALS AND METHODS
Materials
Clofarabine was provided by Genzyme Europe 
(Naarden, The Netherlands), while temsirolimus (CCI-
779, Torisel®) was from Pfizer Inc. (New York, NY, USA). 
For western blotting analysis, primary antibodies were 
purchased from Cell Signaling Technology (Danvers, MA, 
USA). All the antibodies for flow cytometry were from 
Beckman Coulter (Miami, FL, USA). 
Cell culture and primary samples
The AML cell lines were grown in RPMI 1640, 
supplemented with 10% fetal bovine serum (FBS). All 
cell lines, except U937, were from Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH 
(Braunschweig, Germany), and were characterized as 
specified (http://www.dsmz.de/human_and_animal_cell_
lines/main.php?contentleft_id=21). Peripheral blood 
or bone marrow primary cells from AML patients were 
obtained with informed consent according to Institutional 
guidelines, isolated using Ficoll-Paque (GE Healthcare, 
Little Chalfont, UK), and cultured in RPMI 1640 with 
20% FBS. 
Cell viability analysis
MTT (3-[4,5-Dimethylthythiazol-2-yl]-2,5-
Diphenyltetrazolium Bromide) assays were performed 
to assess the sensitivity of cells to drugs, as previously 
described [47, 48].
Combined drug effect analysis 
The combination effect and a potential synergy 
were evaluated from quantitative analysis of dose-effect 
relationships, as described elsewhere [49]. For each 
combination experiment, a CI (combination index) number 
was calculated using the Biosoft CalcuSyn software. This 
method of analysis generally defines CI values of 0.9 
to 1.1 as additive, 0.3 to 0.9 as synergistic, and <0.3 as 
strongly synergistic, whereas values >1.1 are considered 
antagonistic. 
Cell cycle analysis
Flow cytometric analysis was performed using a 
PI/RNase A staining according to standard procedures, as 
described previously [50]. 
Annexin V-FITC/PI staining
To determine the extent of apoptosis induction, 
flow cytometric analysis of Annexin V-FITC/PI-stained 
samples was performed [20]. Samples were analyzed on 
an FC500 flow cytometer (Beckman Coulter) with the 
appropriate software (CXP, Beckman Coulter). 
Flow cytometric detection of AML blasts and LICs
Bone marrow mononuclear cells from AML patients 
were separated by Ficoll/Hypaque density centrifugation 
and stained with a PE-conjugated anti-CD33 and a 
PC7-conjugated anti-CD45 antibody. They were then 
washed with phosphate-buffered saline and processed 
for intracytoplasmic staining of either p-Akt or p-S6RP, 
using AlexaFluor488®-conjugated antibodies, as reported 
elsewhere [14]. 
For LICs detection, a total of 5×105 primary AML 
blast cells were stained with the following conjugated 
antibodies: CD34-PC5, CD38-PC7, and CD123-PE. 
In some cases cells were further stained with Annexin 
V-FITC, while in others they were permeabilized and 
stained with AlexaFluor® 488-conjugated antibodies to 
either p-Akt or p-S6RP [51]. 
Analyses were performed on a Navios (Beckman 
Coulter) flow cytometer equipped with Kaluza software 
(Beckman Coulter). Isotypic controls of the corresponding 
fluorochromes were used to define the threshold for 
positive-staining cells.
Western blotting analysis 
This was performed by standard methods, as 
previously reported [52]. Analysis with an antibody to 
either GAPDH or β-actin documented equal protein 
loading.
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TEM analysis
This was performed according to standard 
techniques [53], using a Philips CM10 (Philips, 
Eindhoven, The Netherlands) transmission electron 
microscope. Images were recorded on a Megaview III 
digital camera (Olympus, Tokyo, Japan).
7-Methyl-GTP cap affinity assay
A total of 5 ×106  AML cells were lysed by 3 freeze-
thaw cycles in 600 μL of solubilization buffer [20 mM N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid/KOH, 
pH 7.6, 200 mM KCl, 0.5 mM ethylenediaminetetraacetic 
acid (EDTA), 20 mM KF, 1 mM K
4
P
2
O
7
, 10% glycerol, 
1% NP40, protease inhibitors and 50 μg/mL RNAse-A]. 
Cell lysates were clarified by centrifugation (13000 rpm, 
20 min, 4°C), and supernatants were incubated (2 h, 4°C) 
with 7-Methyl-GTP-Sepharose beads (GE Healthcare) 
in 400 μL binding buffer (50 mM Tris/HCl, pH 7.5, 300 
mM KCl, 1 mM EDTA, 20 mM KF, 1 mM K
4
P
2
O
7
, 1 mM 
dithiothreitol, and protease inhibitors). Beads were then 
washed 3 times in binding buffer and boiled in Laemmli’s 
sample buffer  [30].
STAT3 and c-Myc expression analysis by qRT-PCR
Total RNA was extracted using the RNeasy Mini 
Kit (Qiagen, Venlo, The Netherlands) according to the 
manufacturer’s instructions and 1 μg of total RNA was 
reverse transcribed using Moloney Murine Leukemia 
Virus Reverse Transcriptase (M-MLV RT) and Oligo(dT) 
15 primer in the presence of dNTPs (Promega, Fitchburg, 
WI, USA). STAT3 and c-Myc gene expression was 
assessed using The TaqMan® Gene Expression Master 
Mix, the assays Hs00374280_m1 and Hs00905030_m1 
respectively, and the 7300 real-time PCR system (Applied 
Biosystems, Foster City, CA, USA). Results were 
normalized to the level of the ubiquitously expressed RNA 
18S ribosomal 1 gene (RN18S, Hs03928990_g1) and were 
expressed as 2-∆∆Ct.
Statistical evaluation 
The data are presented as mean values from three 
separate experiments ± s.d. Data were statistically 
analyzed by a Dunnet test after one-way analysis of 
variance (ANOVA) at a level of significance of p < 0.05 
vs. control samples. 
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